~~<i id='6B70F17492'><strike id='6B70F17492'><tt id='6B70F17492'><pre id='6B70F17492'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：comprehensive 2025-10-01 20:18:00 Page View：54199

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cassava Sciences’ Alzheimer’s clinical trials should be halted
Next article： Cancer drug shortages should be causing more outrage

comprehensive

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Roivant's CEO is a star, but biotech's black hole persists

MollyFerguson/STATRoivantSciences’MattGlinemightbethisyear’sbestbiopharmaCEO,andotherthoughtsaboutMo

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

The biotech scorecard for the 2nd quarter: 12 industry events to watch

APStockIntroducingSTAT’sBiotechQ2Scorecard,ouremoji-enabledmeansoftracking12make-or-breakeventsexpec